<DOC>
	<DOCNO>NCT00557505</DOCNO>
	<brief_summary>P-cadherin may play part tumor growth ; PF-03732010 new drug inhibit P-cadherin . This study test well drug tolerate , effect might . Blood also take measure amount drug blood .</brief_summary>
	<brief_title>A Study Of PF-03732010 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced solid tumor refractory ( intolerant ) establish therapy know provide clinical benefit , standard therapy Age &gt; = 18 year age Adequate bone marrow function define : absolute neutrophil count ( ANC ) ≥1500/uL , hemoglobin ≥ 9 g/dL , platelet &gt; 100,000/uL Adequate liver function define : bilirubin &lt; 1.5 x ULN , AST , ALT ALP &lt; 2.5 x ULN , &lt; 5 x ULN document liver and/or bone metastasis Serum creatinine &lt; 1.5 x ULN ECOG status 01 Availability biopsy tumor tissue ( fine needle aspirate ) test Pcadherin expression Tumor tissue ( fine needle aspirate ) show overexpression Pcadherin Must able give write informed consent Be able comply schedule study visit , treatment plan , laboratory test procedure Chemotherapy , radiotherapy , investigational cancer therapy within 4 week study entry Patients carcinomatous meningitis untreated brain metastasis . History significant low platelet count , and/or bleed disorder , require medical surgical intervention History significant bleeding episode within 6 month , unless source bleeding resect</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>